A recent study conducted in Japan has raised concerns about the potential link between the mRNA-Lipid Nanoparticle (mRNA-LNP) vaccine and increased cancer mortality rates. The study found statistically significant increases in age-adjusted mortality rates for all cancer types, as well as specific types such as ovarian cancer, leukemia, prostate, lip/oral/pharyngeal, pancreatic, and breast cancers. These increases were observed in 2022 after two-thirds of the Japanese population had received the third or later dose of the SARS-CoV-2 mRNA-LNP vaccine.
The researchers suggest that these marked increases in mortality rates may be attributable to mechanisms related to the mRNA-LNP vaccination itself, rather than the COVID-19 infection or reduced cancer care due to lockdown measures. Several case reports have described the development or worsening of cancer after vaccination, indicating a possible causal link between cancer and mRNA-LNP vaccination.
The study analyzed official statistics from Japan to compare observed annual and monthly mortality rates with predicted rates based on pre-pandemic figures. No significant excess mortality was observed during the first year of the pandemic (2020). However, excess cancer mortalities were observed in 2021 after mass vaccination with the first and second vaccine doses. The most significant excess mortalities were observed for all cancers and specific types in 2022 after mass vaccination with the third dose.
Notably, lung, colorectal, stomach, pancreatic, and liver cancers accounted for 61% of deaths from all cancers. The age-adjusted mortality rates for these cancers showed a decreasing trend until the first year of the pandemic but slowed down in 2021 and 2022.
As of March 2023, approximately 80% of the Japanese population had received the first and second doses of the mRNA-LNP vaccine, 68% had received the third dose, and 45% had received the fourth dose.
Watch the video below for more information:
